Editas Medicine, Inc. (EDIT)
EDIT moved a median of -1.15% 30 minutes after news, and -1.41% by the close. How EDIT actually reacts to news — the realized, point-in-time move the market made, measured across 253 labeled events over the last three years with zero look-ahead.
EDIT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.17% | 45% | 253 |
| 30-min | -1.15% | 39% | 253 |
| 60-min | -0.87% | 37% | 253 |
| to close | -1.41% | 39% | 251 |
| Middle 50% of EDIT reactions | -2.56% to +1.90% |
|---|---|
| Median reaction (30-min) | -1.15% |
| Measured reactions | 253 |
Half of all Editas Medicine, Inc. news events land between -2.56% and +1.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EDIT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 28 | -1.20% | 43% | -0.76% |
| Analyst downgrades | 25 | -2.28% | 36% | -3.03% |
| Rating reiterations | 43 | -0.43% | 33% | -0.66% |
| Price-target cuts | 18 | -0.13% | 44% | -0.72% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how EDIT ranks against every other measured name →
That’s how EDIT usually reacts — get an email when it moves on news →Email me when EDIT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EDIT's baseline. Nothing else.
Recent EDIT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference | Press release | GlobeNewswire | -1.65% | -6.20% | |
| Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Press release | GlobeNewswire | -0.37% | +4.03% | |
| Form 8-K Editas Medicine, Inc. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +4.03% | |
| Editas Medicine Reports Inducement Grants to New Chief Medical Officer | Press release | GlobeNewswire | +0.50% | -7.67% | |
| Form EFFECT Editas Medicine, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.50% | -7.67% | |
| Form S-8 Editas Medicine, Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.99% | -4.33% | |
| Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Press release | GlobeNewswire | -1.57% | -4.72% | |
| Editas Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.00% | +2.33% | |
| Form S-3 Editas Medicine, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.00% | +2.33% | |
| Editas Medicine Announces Second Quarter 2026 Results and Business Updates | Press release | GlobeNewswire | +4.96% | +2.84% | |
| Form 10-Q Editas Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.96% | +2.84% | |
| Form 8-K Editas Medicine, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +4.96% | +2.84% | |
| Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. | Press release | GlobeNewswire | +1.43% | -1.43% | |
| Form 8-K Editas Medicine, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +4.44% | +3.70% | |
| Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference | Press release | GlobeNewswire | -4.67% | +0.88% | |
| Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering | Press release | GlobeNewswire | +19.92% | +27.80% | |
| Editas Medicine Announces Proposed Public Offering | Press release | GlobeNewswire | +19.92% | +27.80% | |
| Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress | Press release | GlobeNewswire | +19.92% | +27.80% | |
| Form 8-K Editas Medicine, Inc. For: May 25 | SEC filing · Form 8-K | SEC EDGAR | +19.92% | +27.80% | |
| Form 8-K Editas Medicine, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +19.92% | +27.80% | |
| Form S-3MEF Editas Medicine, Inc. | SEC filing · Form S-3MEF | SEC EDGAR | +19.92% | +27.80% | |
| Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | Press release | GlobeNewswire | -0.69% | -1.72% | |
| Form 8-K Editas Medicine, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | -1.72% | |
| Editas Medicine Announces First Quarter 2026 Results and Business Updates | Press release | GlobeNewswire | +1.32% | +0.66% | |
| Form 10-Q Editas Medicine, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.97% | +2.42% | |
| Form 8-K Editas Medicine, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.32% | +0.66% | |
| Form ARS Editas Medicine, Inc. For: Apr 28 | SEC filing · Form ARS | SEC EDGAR | -0.17% | -5.69% | |
| Form DEF 14A Editas Medicine, Inc. For: Apr 28 | SEC filing · Form DEF | SEC EDGAR | -0.17% | -5.69% | |
| Form DEFA14A Editas Medicine, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.17% | -5.69% | |
| Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences | Press release | GlobeNewswire | +2.44% | +6.62% | |
| Form 8-K Editas Medicine, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -1.21% | -4.50% | |
| Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | Press release | GlobeNewswire | -1.75% | -2.19% | |
| Form 8-K Editas Medicine, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -2.19% | |
| Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Press release | GlobeNewswire | +8.33% | +17.17% | |
| Form 10-K Editas Medicine, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.98% | +9.54% | |
| Form 8-K Editas Medicine, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +8.33% | +17.17% | |
| Editas Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.98% | +6.78% | |
| Editas Medicine Announces Third Quarter 2025 Results and Business Updates | Press release | GlobeNewswire | -2.42% | -5.97% | |
| Form 10-Q Editas Medicine, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.05% | +2.70% | |
| Form 8-K Editas Medicine, Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -2.42% | -5.97% | |
| Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 | Press release | GlobeNewswire | -0.97% | -0.65% | |
| Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress | Press release | GlobeNewswire | -0.98% | -0.12% | |
| Form 8-K Editas Medicine, Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | -11.22% | |
| Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.74% | -4.52% | |
| Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus | Press release | Canada Newswire | -1.21% | -2.71% | |
| Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | Press release | GlobeNewswire | +1.19% | -1.98% | |
| Form 8-K Editas Medicine, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | -1.98% | |
| Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate | Press release | GlobeNewswire | -0.38% | -3.02% | |
| Editas Medicine to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.37% | -2.20% | |
| Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Press release | GlobeNewswire | +7.85% | +25.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EDIT section they belong to.
Where else EDIT is measured.
EDIT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cerus Corporation (CERS) | 255 | +0.09% | 52% |
| Avalon GloboCare Corp. (AVCO) | 254 | 0.00% | 41% |
| Nevro Corp. (NVRO) | 253 | 0.00% | 49% |
| DarioHealth Corp. (DRIO) | 252 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Editas Medicine, Inc.'s median reaction calculated?
Every labeled EDIT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 253 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of EDIT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EDIT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.